Nanologica Q1 2025: Initial take – largely as expected - Redeye
Redeye leaves its initial comments on Nanologica's Q1 report which came in largely as expected showing minor positive deviation on sales and a slight shortfall in EBITDA.
ANNONS
Redeye leaves its initial comments on Nanologica's Q1 report which came in largely as expected showing minor positive deviation on sales and a slight shortfall in EBITDA.